PTC completes acquisition of ST-920 Fabry disease gene therapy
PTCT - PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
Story updates
08:30:39 PM UTC
SquawkNews
PTCT PTCT - PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
08:30:52 PM UTC
SquawkNews
Completion of BLA submission expected in Q4 2026 —WARREN, N.J., Sept. 21, 2026 // -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 — a BLA-stage, one-time administered AAV gene…
08:31:25 PM UTC
SquawkNews
PTC Therapeutics completed the acquisition of ST-920, a BLA-stage AAV gene therapy for Fabry disease, and expects to complete a rolling BLA submission to the FDA for accelerated approval in Q4 2026.Material DetailsContext by AI AnalystThis is a mid-cycle pipeline build, moving an acquired late-stag…
08:44:57 PM UTC
SquawkNews
PTC Therapeutics completed acquisition of ST-920 and expects to finish a rolling BLA submission for accelerated FDA approval in Q4 2026.Key Highlights:Original SEC Filing: PTC THERAPEUTICS, INC. [ PTCT ] - 8-K - Sep. 21, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verif…